Abstract
The Therapeutics for Rare and Neglected Diseases (TRND) program (http://ncats.nih.gov/trnd.html) seeks to encourage and speed the development of new treatments for diseases of limited commercial interest to the biopharmaceutical industry. Faced with constrained financial resources and the inherent risk of failure during development, industry must make strategic decisions regarding therapeutic commercialization [1,2]. Often, so-called rare diseases of low prevalence, as defined in the amended Orphan Drug Act [3,4], as well as high-prevalence neglected diseases (http://www.who.int/neglected_diseases/diseases/en/) occurring chiefly among impoverished populations in the developing world, go unaddressed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
